Clinical / Obesity / Brain / BioTech / Biotech / Drug / Drugs / National blog main / New York / New York blog main / New York top stories / Alexandria Venture Investments / bill gates / Casdin Capital / Charles Zuker / Columbia University / Euclidean Capital / Greenspring Associates / Gut-brain Axis / Illumina Ventures / Kallyope / Lasker Award / Life Sciences / Lux Capital / Nancy Thornberry / nobel / obesity / Polaris Partners / Richard Axel / The Column Group / Tom Maniatis / Two Sigma Ventures

Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic

Posted On: Mar 25, 2020   |   Posted By: Xconomy

Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic

Kallyope, one of New York's best funded biotechs, has secured more than $100 million to move two of its programs into the clinic-including its most advanced, an experimental drug designed to treat obesity. The company was founded in 2015 with $44 million to leverage new learnings about the “gut-brain axis”-pings of communication between our guts and our central nervous system-to make drugs for a range of diseases. Since then the company has raised $199 million more across two subsequent rounds of funding, including a $112 million Series C financing announced Wednesday, and advanced two programs to the cusp of human testing...

Continue reading ...